We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Test for Major Forms of Congenital Color Blindness Launched

By LabMedica International staff writers
Posted on 19 Jun 2012
Print article
A military grade genetic test for all major forms of congenital color blindness has been launched.

The test, marketed under the Eyedox brand, involves a painless finger prick to obtain a blood sample that is specifically analyzed using gene sequencing technology for color genes, which are expressed in the eye but present in all cells. This gives both a precise identification and an accurate classification of any inherited color vision deficiency along with a precise severity rating.

It is the first totally objective color-vision test that can consistently separate colorblind individuals from those with normal color vision and accurately classify color vision deficiencies. It offers uniform standards in the workplace and meets the color vision testing requirements of military and government organizations grappling with badly outdated testing methods.

The test was launched at the Aerospace Medical Association annual event May 13-15, 2012, in Atlanta, Georgia. The genetic test, and much of what is known about color vision itself, represents decades of research by the husband and wife team of Jay and Maureen Neitz, PhD, who are professors of Ophthalmology, and Biological Structure at the University of Washington (Seattle, WA, USA). A significant improvement over conventional color vision tests is the ability of the genetic test to rate the severity of the highly variable condition on a scale of 1 to 100.

The test was developed by Genevolve Vision Diagnostics, Inc. (Albuquerque, NM, USA) a life sciences company, which researches, designs, and commercializes noninvasive molecular diagnostic assays and treatments for clinical applications for the color vision industry.

“The new military grade test is near perfect at separating color normals from color defectives which has proved challenging with conventional testing methods,” said Genevolve president Matt Lemelin.

Congenital or inherited colorblindness affects the photoreceptors that absorb light in the red-green visual spectrum. Color vision deficiency is the most common genetic disorder in humans. The disorder is most often inherited as the result of mutations on the X chromosome and therefore is predominantly present in the male population. It has been estimated that 1 out of 8 males and 1 out of 200 females possess some form of inherited color vision deficiency. Studies indicate there are 13.5 million color vision deficients in the United States and more than 200 million worldwide.

The test has been designed to meet the needs of the Federal Aviation Administration and the US Air Force as the departments and others have been critical of the failure of color vision tests currently on the market meeting their requirements. Highlighting testing failures and prompting the National Travel Safety Bureau to recommend new color vision testing standards was the 1997 Amtrak train disaster blamed on a colorblind engineer that misread colored signals and the 2002 Fed Ex plane crash labeling the first officer’s undetected colorblindness as a contributing factor.

Related Links:

University of Washington
Genevolve Vision Diagnostics, Inc.
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.